SIM
NTLA icon

Spark Investment Management’s Intellia Therapeutics NTLA Stock Holding History

Spark Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-23,290
Closed -$497K – 866
2016
Q2 		$497K Buy
+23,290
New +$620K 0.05% 462

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Spark Investment Management's NTLA Position: Q3 2016 in Review

Spark Investment Management sold out of Intellia Therapeutics (NTLA) in Q3 2016, closing a stake of 23,290 shares — an estimated $497K sold.

Spark Investment Management first reported a position in NTLA in Q2 2016 and held it in 1 quarter. The position peaked at $497K in Q2 2016. 65 funds tracked by Wall St. Rank hold NTLA as of Q3 2016.

  • Spark Investment Management reported no remaining Intellia Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Spark Investment Management sold 23,290 Intellia Therapeutics shares in Q3 2016, an estimated $497K.
  • Spark Investment Management first reported a position in Intellia Therapeutics in Q2 2016 and held it in 1 quarter.
  • Spark Investment Management's Intellia Therapeutics position peaked at $497K in Q2 2016.
  • 65 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2016.

Based on Spark Investment Management's 13F filing for Q3 2016, filed 10 Nov 2016.